Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30010
Title: Factor Xa Inhibition for the Treatment of Venous Thromboembolism Associated With Cancer: A Meta-Analysis of the Randomised Controlled Trials.
Austin Authors: Murphy, Alexandra C ;Koshy, Anoop N ;Farouque, Omar ;Yeo, Belinda ;Raman, Jaishankar;Kearney, Leighton G ;Yudi, Matias B 
Affiliation: Cardiology
Olivia Newton-John Cancer Wellness and Research Centre
Department of Medicine, Deakin University, Geelong, Vic, Australia
Department of Medicine, The University of Melbourne, Vic, Australia
Department of Medicine, The University of Illinois, Urbana-Champaign, IL, USA
Issue Date: May-2022
Date: 2021-12-09
Publication information: Heart, Lung & Circulation 2022; 31(5): 716-725
Abstract: Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients. Until recently, guidelines recommended the use of low-molecular weight heparin (LMWH) as standard of care for VTE in patients with cancer. Despite the proven efficacy of direct oral anticoagulants (DOACs) for treatment of VTE, there is equipoise supporting their use in cancer patients. A systematic review of PubMed, Medline and EMBASE identified four randomised controlled trials (RCTs) in patients with cancer and VTE comparing a factor Xa inhibitor (FXaI) to LMWH. A meta-analysis was performed with a primary outcome of VTE recurrence and key secondary outcomes of major bleeding, clinically relevant non-major bleeding (CRNMB) and gastrointestinal (GI) bleeding. Four RCTs with 2,907 patients were included. 1,451 patients were randomised to FXaI and 1,456 to LMWH. VTE recurrence was lower in the FXaI group (RR 0.62, 95%CI 0.44-0.87; p=0.01; I2=24.90), with an absolute risk difference of -4% equating to a number needed to treat of 25 for prevention of recurrent VTE with FXaI. No significant difference in major bleeding was noted between groups (RR 1.33, 95%CI 0.84-2.11; p=0.23). Rates of GI bleeding (RR 1.87, 95%CI 1.06-3.29; p=0.03) and CRNMB (RR 1.57, 95%CI 1.11-2.23; p=0.01) were greater with FXaIs. In patients with cancer and VTE, the rate of VTE recurrence was significantly lower with FXaI than with LMWH without an increased risk of major bleeding. Our data supports the use of FXaIs as the standard of care for the treatment of VTE in this population.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30010
DOI: 10.1016/j.hlc.2021.10.024
ORCID: 0000-0002-4248-7537
0000-0002-8741-8631
0000-0003-2821-1451
0000-0002-9218-9917
0000-0002-7691-4779
0000-0002-3706-4150
Journal: Heart, Lung & Circulation
PubMed URL: 34896013
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/34896013/
Type: Journal Article
Subjects: Anticoagulation
Cancer
Cardio-oncology
Direct oral anticoagulation
Factor Xa inhibitor
Low molecular weight heparin
Venous thromboembolism
Appears in Collections:Journal articles

Show full item record

Page view(s)

36
checked on Apr 14, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.